(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Study sponsor: Cogent Biosciences, Inc. · COGT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-05-22Actual
Enrollment · participants237Estimated
Source updated2026-10-22Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.